US 11,815,517 B2
Antibodies to 25-hydroxyvitamin D2 and D3
Niver Panosian Sahakian, Encino, CA (US); Bruce A. Campbell, Calabasas, CA (US); Spencer Hsiang-Hsi Lin, Walnut Creek, CA (US); James Vincent Freeman, Sandy Hook, CT (US); Qimu Liao, Alhambra, CA (US); and Ramon A. Evangelista, Laguna Hills, CA (US)
Assigned to Siemens Healthcare Diagnostics Inc., Tarrytown, NY (US)
Filed by Siemens Healthcare Diagnostics Inc., Tarrytown, NY (US)
Filed on Nov. 3, 2020, as Appl. No. 17/087,914.
Application 17/087,914 is a division of application No. 15/915,001, filed on Mar. 7, 2018, granted, now 10,837,973.
Application 15/915,001 is a continuation of application No. 14/335,686, filed on Jul. 18, 2014, abandoned.
Application 14/335,686 is a continuation of application No. 13/458,847, filed on Apr. 27, 2012, granted, now 8,785,603, issued on Jul. 22, 2014.
Claims priority of provisional application 61/488,630, filed on May 20, 2011.
Prior Publication US 2021/0055314 A1, Feb. 25, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/82 (2006.01); C07K 16/44 (2006.01)
CPC G01N 33/82 (2013.01) [C07K 16/44 (2013.01); G01N 2800/02 (2013.01)] 10 Claims
 
1. A cell that produces a monoclonal antibody, or an antigen-binding fragment thereof, that binds 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3, wherein the monoclonal antibody comprises:
a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 16; and
a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 32.